Abzena will be in attendance at the upcoming PBSS San Francisco workshop on Sept. 10th: Translational PK/PD and Human Dose Projection for Antibodies/ADCs and Novel Therapeutic Modalities

Vice Presidents of Business Development Sudha Krishnan and Zoe Yi Zhang will be on hand to learn about your antibody program’s needs. Schedule a meeting below to connect with them and learn how Abzena can help rapidly move your antibody forward from discovery through commercial launch.

With decades of experience in designing, developing, and manufacturing antibody and antibody-drug conjugate (ADCs) programs, our team leverages deep scientific and technical know-how to bring compounds to market- finding the best solutions and technologies to achieve the best project outcome.